Abstract

There is described a triboelectric device. The triboelectric device generally having: a resilient structure having a deformation plane, and a plurality of hollow cells having internal walls having a cross-sectional shape extending along a respective cell axis perpendicular to the deformation plane, the internal walls defining a cavity thereinside, and having first and second curved surfaces distributed around the cavity and facing the cavity; and a triboelectric circuit having a first electrode assembly covering the first curved surfaces, a second electrode assembly covering the second curved surfaces, the first and second electrode assemblies electrically insulated from one another; wherein, when the resilient structure is deformed along the deformation plane, the first and second electrode assemblies perform a movement relative to one another thereby creating a flow of electric charges across the triboelectric circuit.

IPC Classes  ?

• H05F 7/00 - Use of naturally-occurring electricity

Abstract

An energy conversion system includes a reactor vessel, a jacket disposed within the reactor vessel, the jacket having a wall that defines a chamber, a first end, and a second end opposite the first end, and a nozzle coupled to the reactor and arranged to direct a continuous flow of fuel at a flow rate into the chamber. The fuel including a mixture of a metal compound and water at a pressure that is greater than 221 bar. A cooling space is formed between the jacket and the reactor vessel and is operable to maintain a temperature of the fuel within the chamber between 374 and 800 degrees Celsius. A first gas outlet is in fluid communication with the chamber and is arranged to discharge a gas, and an outlet is in fluid communication with the chamber and is arranged to continuously discharge a reaction product and water.

IPC Classes  ?

• B01J 19/24 - Stationary reactors without moving elements inside
• B01J 3/00 - Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matterApparatus therefor
• B01J 4/00 - Feed devicesFeed or outlet control devices

Abstract

There is provided A compound of formula I, a salt or solvate thereof as described herein, for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative disorders, colorectal cancer, medulloblastoma, renal, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous cancer, gastrointestinal stromal tumor, glioma, myxofibrosarcoma, leiomyosarcoma, neuroblastoma, synovial sarcoma, mesothelioma, gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer, and neural cancer.

IPC Classes  ?

• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61P 35/00 - Antineoplastic agents

Abstract

There is provided a pharmaceutical combination comprising a cyclooxygenase (COX) inhibitor and a compound having the Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof. In some embodiments, the COX inhibitor can comprise a Non-Steroidal Anti-Inflammatory Drug (NSAID). The pharmaceutical combination can be used in the treatment of pain in a subject in need thereof, such inflammatory pain. There is also provided a kit comprising a first single dose form of a cyclooxygenase (COX) inhibitor and a second single dose form of a compound having the Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and instructions for use. (I)

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present application relates to surface modification of polymers. More specifically, the present application relates to polymeric material having hydrophobic and oleophilic surface, methods for preparing the same, and uses of the modified polymers for capture of non-polar, apolar, hydrophobic or amphiphilic compounds from a polar solvent. The present application includes use of the surface-modified polymers in capture of non-polar compounds in water, such as oil, diesel, long chain alkanes, alkenes, alkynes, paraffin, pharmaceutical compounds and combinations thereof.

IPC Classes  ?

• C08J 7/02 - Chemical treatment or coating of shaped articles made of macromolecular substances with solvents, e.g. swelling agents
• C08F 110/02 - Ethene
• C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
• C08G 63/91 - Polymers modified by chemical after-treatment
• C09K 3/32 - Materials not provided for elsewhere for treating liquid pollutants, e.g. oil, gasoline or fat

Abstract

There is described a method of manufacturing an array of gallium nitride (GaN) nanowires via selective area growth. The method generally has: mounting a substrate to a substrate holder face exposed within a growth cavity, the substrate having a base layer and a mask covering the base layer, the mask having a plurality of apertures spaced apart from one another and exposing the base layer thereunder; while heating the growth cavity at a given surface temperature ranging between about 650 °C and 750 °C when measured on a side of the substrate holder face to which the substrate is mounted, directing gallium (Ga) and nitrogen (N) atoms towards the selective area growth mask at a gallium growth rate below about 10 nm/min and a nitrogen growth rate below 5 nm/min, respectively, said heating and said directing selectively growing the GaN nanowires at corresponding ones of the apertures.

IPC Classes  ?

• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• C30B 25/04 - Pattern deposit, e.g. by using masks
• C30B 29/40 - AIIIBV compounds
• C30B 29/62 - Whiskers or needles
• H01L 21/20 - Deposition of semiconductor materials on a substrate, e.g. epitaxial growth

Abstract

A system for determining the presence of a gas bubble in a blood sample. The system has a microfluidic chip comprising a plurality of interconnected microfluidic channels arranged in a vascular-like configuration to mimic a given part of a vascular system, with a first inlet for receiving the blood sample and a second inlet for injecting the gas into a flow of the fluid to create the gas bubble in the microfluidic channels. The system has a circulation system comprising a pump, a reservoir containing the blood sample and in communication with the pump, and a conduit in communication with the pump and/or the reservoir, the conduit directing the blood sample to the first inlet. The system also has an imaging system configured to capture images of the microfluidic channels of the microfluidic chip, and a detection system configured to determine the presence and location of the gas bubble.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61G 10/02 - Treatment rooms for medical purposes with artificial climateTreatment rooms for medical purposes with means to maintain a desired pressure, e.g. for germ-free rooms
• A61K 31/02 - Halogenated hydrocarbons
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/10 - Investigating individual particles
• G09B 23/30 - Anatomical models
• B81B 1/00 - Devices without movable or flexible elements, e.g. microcapillary devices

Abstract

There is provided a method of manufacturing a disordered rocksalt-cathode active material of Formula 1: There is provided a method of manufacturing a disordered rocksalt-cathode active material of Formula 1: Li0.4+xM1yM2zO2−kFk  (1) Wherein, 0

IPC Classes  ?

• C01G 45/12 - Complex oxides containing manganese and at least one other metal element
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/13915 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx containing halogen atoms, e.g. LiCoOxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

There is provided a cathode comprising a disordered rock salt-cathode active material, a carbon nanotube-based conductive material and a binder. The disordered rock salt-cathode active material has a composition as per Chemical Formula 1: There is provided a cathode comprising a disordered rock salt-cathode active material, a carbon nanotube-based conductive material and a binder. The disordered rock salt-cathode active material has a composition as per Chemical Formula 1: Li0.4+xM1yM22O2−kFk   (1) There is provided a cathode comprising a disordered rock salt-cathode active material, a carbon nanotube-based conductive material and a binder. The disordered rock salt-cathode active material has a composition as per Chemical Formula 1: Li0.4+xM1yM22O2−kFk   (1) wherein, 0

IPC Classes  ?

• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/052 - Li-accumulators

Abstract

A method of evaluating a binocular imbalance between left and right eyes of a subject, is provided. The method includes selecting a stimulus condition including quality values selected from a numerical scale that quantifies a perceptible quality of an image; concurrently displaying a plurality of images to the subject based on the stimulus condition, the plurality of images including a left-eye image and a right- eye image displayed with their perceptible qualities defined by the quality values; receiving an input from the subject sequentially ranking an apparent perceived quality of the plurality of images; and calculating a scaling factor defining a relative imbalance in subjective quality between the subject's left eye and right eye, based on the sequential ranking. A corresponding system and computer-readable medium are also provided.

IPC Classes  ?

• A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus

Abstract

The thermoelectromechanical system can have a porous structure having a spinodoid geometry and formed of an electrically polarized ferroelectric material, the structure occupying a volume and having a first area spaced apart from a second area; and a device electrically connected to the first area and to the second area.

IPC Classes  ?

• H10N 30/85 - Piezoelectric or electrostrictive active materials
• H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte
• H10N 30/045 - Treatments to modify a piezoelectric or electrostrictive property, e.g. polarisation characteristics, vibration characteristics or mode tuning by polarising

Abstract

A seal has: a metallic substrate; and a coating layer, The coating layer has in atomic percent of all metals in the coating layer: 6.5 to 22.0 Al; 14.0 to 23.0 Fe; 14.0 to 23.0 Co; 14.0 to 23.0 Cr; 14.0 to 23.0 Mn; and 14.0 to 23.0 Ni. The coating may be applied by high velocity oxy-fuel (HVOF) spray.

IPC Classes  ?

• C23C 4/073 - Metallic material containing MCrAl or MCrAlY alloys, where M is nickel, cobalt or iron, with or without non-metal elements
• C22C 30/00 - Alloys containing less than 50% by weight of each constituent
• C23C 4/129 - Flame spraying
• F01D 11/00 - Preventing or minimising internal leakage of working fluid, e.g. between stages

Abstract

A method for applying a coating, includes: providing a mixture of powders of comprising by volume percent: 10.0 to 60.0 one or more cobalt-based alloys and 5.0 to 70.0 WC—Ni; and spraying the mixture on a metallic substrate. Each of the cobalt-based alloys have by weight percent: Co as a largest constituent; 20.0-35.0 Cr; up to 3.0 C, if any; and up to 4.0 Ni, if any.

IPC Classes  ?

• C23C 4/06 - Metallic material
• C22C 19/07 - Alloys based on nickel or cobalt based on cobalt
• C23C 4/10 - Oxides, borides, carbides, nitrides or silicidesMixtures thereof
• C23C 4/129 - Flame spraying

Abstract

A method for repairing damage at a damage site on the surface of a nickel- or cobalt-based alloy. The method includes: machining at the damage site; and applying a high entropy alloy (HEA) repair material to the damage site via high velocity oxy-fuel (HVOF) spray, high velocity air-fuel (HVAF) spray, or cold spray.

IPC Classes  ?

• F02C 3/14 - Gas-turbine plants characterised by the use of combustion products as the working fluid characterised by the arrangement of the combustion chamber in the plant
• C22C 30/00 - Alloys containing less than 50% by weight of each constituent
• C23C 4/08 - Metallic material containing only metal elements
• C23C 4/129 - Flame spraying
• F02C 7/28 - Arrangement of seals

Abstract

Methods and systems for phenotyping based on a neural network model are provided. Training the model includes generating a dataset of individual-specific variant graphs associated representing dependencies among variants in individuals' genomes based on biomedical domain knowledge labelled according to target phenotype values to be predicted, and training the model using the training dataset to generate a phenotype prediction from an input individual-specific variant graph. Measure the contribution of a genetic variant to a phenotype of a target individual includes generating an individual-specific variant graph for the individual, modifying the individual-specific variant graph to remove a genetic variant, providing the initial and the modified individual-specific variant graphs as input to the phenotyping neural network model to generate two phenotype predictions, and calculating a difference between the two predictions, providing a measure of the contribution of the genetic variant to the phenotype.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G06N 3/042 - Knowledge-based neural networksLogical representations of neural networks
• G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
• G16B 40/20 - Supervised data analysis
• G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks

Abstract

A device for cell differentiation, which may be used for culturing cells for example, includes an enclosure defining a liquid-receiving volume for receiving a liquid media, and an insert received in the enclosure. The insert includes a peripheral wall circumscribing an apical volume and having an opening in a bottom end of the insert. A membrane extends across the opening and defines pores sized to receive cells, with an apical side of the membrane adapted to receive cells thereon. The membrane and the peripheral wall separate the liquid-receiving volume into an apical volume within the insert and a basal volume below the membrane within the enclosure. A source of a pressurized fluid is in fluid flow communication with the basal volume to define a basal pressure in the basal volume that is greater than an apical pressure in the apical volume acting against the apical side of the membrane.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/06 - Apparatus for enzymology or microbiology with gas introduction means with agitator, e.g. impeller

Abstract

An optimization-based decoder with improved performance and cyclic redundancy check is provided. An optimization problem is generated and solved. The optimization problem includes a function implementing constraints on variables. Main variables correspond to nodes of the encoding graph, including input variables corresponding to output nodes and output variables corresponding to input nodes. Ancillary variables correspond to an additional output a logical operations in the encoding graph. Constraints are configured to generate cost penalties, for instance when the main and ancillary variables of a candidate solution disagree with conditions of the encoding graph, and to correspond with the cross-entropy between each codeword symbol and the corresponding input variable. A candidate solution is obtained by solving the optimization problem, wherein the output variables in the candidate solution correspond to decoded symbols.

IPC Classes  ?

• H04L 1/00 - Arrangements for detecting or preventing errors in the information received
• H03M 13/29 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes combining two or more codes or code structures, e.g. product codes, generalised product codes, concatenated codes, inner and outer codes

Abstract

Methods and systems for treatment prioritization using a neural network model are provided. Training the model includes generating an enriched genetic knowledge graph with edges characterizing relationships between genetic variants, genes, diseases, treatments and symptoms, embedding the graph vertices in genetic knowledge vectors, receiving training patient feature value sets, generating a training dataset of training patient vectors labelled with target values comprising treatment efficacity by scaling the genetic knowledge vectors by the patient feature value sets, and training the model to process an input patient vector and generate a predicted efficacity of the at least one treatment option. Performing inferences includes receiving patient feature values characterizing a patient, generating the patient input vector by scaling the genetic knowledge vectors by the patient feature values, and providing the patient input vector as input to the model, thereby generating a treatment efficacy vector predicting efficacity of a plurality of treatment options.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance

Abstract

A method of selecting an action from a plurality of actions to be performed in an environment comprises maintaining. for each action, count data indicative of a number of times the action has been performed and a difference between the number of times and a number of observed resulting rewards for the action, each reward being a numeric value that measures an outcome of a given action, determining. from the count data and a bandit score provided by a bandit model. an expected score for each action, the bandit score provided by the bandit model for a given history of performed actions and observed rewards. and the expected score determined by determining an expected value of the bandit score given a likelihood of some of the actions having unobserved pending rewards. and selecting the action from the actions and based on the expected score for each action.

IPC Classes  ?

• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
• G06F 17/18 - Complex mathematical operations for evaluating statistical data
• G06N 3/092 - Reinforcement learning
• G06Q 50/12 - Hotels or restaurants
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

A quantum processing unit comprises a first and a second multimode interferometer each optically coupled to a first and a second input waveguide arm and to a first and a second output waveguide arm. A first and a second multimode phase shifter respectively interconnect the first interferometer's first output arm and the second interferometer's first input arm, and the first interferometer's second output arm and the second interferometer's second input arm. At least a third phase shifter is optically coupled to one of the second interferometer's output and the first interferometer's input. Each phase shifter is configured to impart respective phase shifts to optical modes of an optical wave.

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

There is described a method of manufacturing an array of gallium nitride (GaN) nanowires via selective area growth. The method generally has: mounting a substrate to a substrate holder face exposed within a growth cavity, the substrate having a base layer and a mask covering the base layer, the mask having a plurality of apertures spaced apart from one another and exposing the base layer thereunder; while heating the growth cavity at a given surface temperature ranging between about 650° C. and 750° C. when measured on a side of the substrate holder face to which the substrate is mounted, directing gallium (Ga) and nitrogen (N) atoms towards the selective area growth mask at a gallium growth rate below about 10 nm/min and a nitrogen growth rate below 5 nm/min, respectively, said heating and said directing selectively growing the GaN nanowires at corresponding ones of the apertures.

IPC Classes  ?

• H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
• H01S 5/323 - Structure or shape of the active regionMaterials used for the active region comprising PN junctions, e.g. hetero- or double- hetero-structures in AIIIBV compounds, e.g. AlGaAs-laser

Abstract

A magnetic valve assembly for a container is disclosed. The container defines a cavity accessible via an opening. The magnetic valve assembly comprises a cap connectable to the container to at least partially close the opening of the container. The cap has an inlet port, a filling port opening into the cavity of the container when the cap is engaged to the container, and a fluid passage extending between the inlet port and the filling port. A buoyant element is sized to be received within the cavity of the container and connectable to the cap to seal the filling port. At least one of the buoyant element and the cap includes a magnet for magnetically connecting the buoyant element to the cap.

IPC Classes  ?

• F16K 31/08 - Operating meansReleasing devices electricOperating meansReleasing devices magnetic using a magnet using a permanent magnet
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B65D 47/00 - Closures with filling and discharging, or with discharging, devices

Abstract

A sole layer for an item of footwear, has a metamaterial, the metamaterial including unit cells interconnected to one another, a unit cell of the unit cell configurable in a selected one of a first configuration and a second configuration, the unit cells being stable in both of the first configuration and the second configuration, the unit cell in the first configuration differing from the unit cell in the second configuration by one or more of an energy absorption, an energy dissipation, an energy return, and a stiffness.

IPC Classes  ?

• A43B 13/12 - Soles with several layers of different materials
• A43B 13/18 - Resilient soles

Abstract

The present disclosure concerns the reduction in the immunosuppression and the increase in the anti-tumor immune cytotoxicity in a tissue by using an antagonist of the type 1 insulin growth factor receptor (IGF-1R). The present disclosure also concerns the combination of the antagonist of the IGF-1R with an immune response activating agent to mitigate the symptom or treat a cancer in a subject.

IPC Classes  ?

• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

It is provided a protocol to induce the formation of lower respiratory tract organoids in only 21 days, the organoids containing markers of both proximal and distal regions. The organoids is obtained by leveraging cellular interactions between airway bronchial epithelial cells and fibroblasts. It is also provided the use of the organoids to study respiratory viral infections with strong similarity to adult lung tissue.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

There is provided a method of selectively differentiating mesenchymal stem cells into a first predetermined cell lineage associated with the nuclear localization of Yes-associated protein (YAP) or into a second predetermined cell lineage associated with the cytoplasmic localization of YAP. The curvature of the nucleus is controlled to have a maximum nuclear curvature (Kmax) of at least 0.5 μm−1 to select for the first predetermined cell lineage, or a Kmax that does not exceed 0.5 μm−1 to select for the second predetermined cell lineage. The mesenchymal stem cells having a controlled nuclear curvature are incubated in a media with or without differentiation additives to obtain the first predetermined cell lineage or the second predetermined cell lineage.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0793 - Neurons

Abstract

A multi-stage transimpedance amplifier comprises a first gain stage cascaded with a second gain stage, the second gain stage's output connected to the first gain stage's inverting input and to the second gain stage's inverting input, a compensation network electrically connected between the first gain stage's output and the second gain stage's output, the first gain stage, the second gain stage, and the compensation network together implementing a transfer function having complex conjugate poles and a real-valued zero, the compensation network comprising a resistor electrically connected in series with a capacitor, the resistance of the resistor and the capacitance of the capacitor determining the positioning of the complex conjugate poles, and a third gain stage cascaded with the second gain stage for introducing an additional pole in the transfer function, the third gain stage's output connected to the second gain stage's non-inverting input.

IPC Classes  ?

• H03F 1/42 - Modifications of amplifiers to extend the bandwidth
• H03F 3/45 - Differential amplifiers

Abstract

There is provided a continuous combustion system for iron particles. The system comprising a multi-annular combustion tube defining in cross-section at least three distinct passages from its inlet to its outlet. A first tube that is innermost, defines a first passage providing a primary air flow with suspended iron particles. A second tube, defines an inner annular space providing a secondary air flow, a pilot combustible flow, and an ignition point of a spark generator. A third tube defines a third passage comprises a swirl generator and provides a tertiary air flow. The tubes are nested in position within the multi-annular combustion tube. The system comprises a divergent nozzle at the outlet of the multi-annular combustion tube: a combustion reactor in fluid communication with the divergent nozzle, for the generation and stabilization of a turbulent iron flame that burns the iron particles and produces oxidized iron particles; and a cyclone.

IPC Classes  ?

• F23C 1/12 - Combustion apparatus specially adapted for combustion of two or more kinds of fuel simultaneously or alternately, at least one kind of fuel being either a fluid fuel or a solid fuel suspended in air gaseous and pulverulent fuel
• F23C 7/00 - Combustion apparatus characterised by arrangements for air supply
• F23C 9/00 - Combustion apparatus characterised by arrangements for returning combustion products or flue gases to the combustion chamber
• F23D 1/00 - Burners for combustion of pulverulent fuel
• F23D 17/00 - Burners for combustion simultaneously or alternately of gaseous or liquid or pulverulent fuel
• F23J 15/02 - Arrangements of devices for treating smoke or fumes of purifiers, e.g. for removing noxious material

Abstract

There is provided a method of producing LLZO having a cubic crystal phase. The method comprises providing an aqueous phase comprising zirconium (Zr) and lanthanum (La). The aqueous phase has a pH of between 7 and 14. An intermediate is formed, the intermediate comprising crystalline La(OH)3 and amorphous Zr hydroxide from the Zr and the La in the aqueous phase. The intermediate is washed and recovered to obtain a washed intermediate. The washed intermediate is heat treated with a Li precursor at a temperature of from 400 to 850° C. to obtain the LLZO.

IPC Classes  ?

• H01M 10/0562 - Solid materials

Abstract

Described are bacterial compositions and uses thereof for controlling, suppressing and/or preventing an infection from Clavibacter michiganensis subsp. michiganensis (Cmm) in tomato. The bacterial compositions comprise an aqueous mixture of living Bacillus subtilis and living Bacillus pumilus. The bacterial compositions can be combined with existing herbicides, insecticides, fungicides, bactericides, and nutrient, including but not limited copper-containing compounds. Combination with a copper fungicide such as Kocide™ provides a synergistic efficacy.

IPC Classes  ?

• A01N 63/22 - Bacillus
• A01N 61/00 - Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• C12N 1/20 - BacteriaCulture media therefor

Abstract

A casting system has: a ladle for containing a volume of molten metal; a tundish located downstream of the ladle and below the ladle; and a ladle shroud fluidly connecting the ladle to the tundish, the ladle shroud extending from an inlet fluidly connected to the ladle to an outlet fluidly connected to the tundish along a central axis, the ladle shroud defining an internal flow passage having a converging section extending from the inlet to a constriction located downstream of the inlet, a cross-sectional area of the internal flow passage taken in a plane normal to the central axis decreasing along the converging section to the constriction, the cross-sectional area at the constriction being less than the cross-sectional area of the internal flow passage anywhere upstream of the constriction, the constriction being aligned with a baseline level of molten metal in the tundish

IPC Classes  ?

• B22D 41/00 - Casting melt-holding vessels, e.g. ladles, tundishes, cups or the like
• B22D 1/00 - Treatment of fused masses in the ladle or the supply runners before casting
• B22D 41/12 - Travelling ladles or similar containersCars for ladles
• B22D 41/58 - Pouring-nozzles with gas injecting means

Abstract

There is provided a compound having the Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof. A pharmaceutical composition comprising the compound or Formula (I) or the pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient is also provided. The compound or pharmaceutically acceptable salt, solvate, or prodrug thereof, or the pharmaceutical composition comprising the same, can be used for the treatment or prevention of a disorder for which an ASICs inhibitor is indicated. In some embodiments, the compound or pharmaceutically acceptable salt, solvate, or prodrug thereof, or the pharmaceutical composition comprising the same, can be used for the treatment or prevention of pain, arthritis, stroke, epileptic disorder, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury.

IPC Classes  ?

• C07D 333/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

There is provided a compound having the Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The compound or pharmaceutically acceptable salt, solvate, or prodrug thereof can be used for the treatment or prevention of a disorder for which an ASICs inhibitor is indicated. There is also provided a use of a compound C having the Formula (I') or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the preparation of a pharmaceutical composition for the treatment or prevention of a disorder for which an ASICs inhibitor is indicated. In some embodiments, the compound Formula (I) or the pharmaceutically acceptable salt, solvate, or prodrug thereof, or the pharmaceutical composition prepared using compound C is for the treatment or prevention of pain, arthritis, stroke, epileptic disorder, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury.

IPC Classes  ?

• C07D 333/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 333/74 - Naphthothiophenes
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 495/20 - Spiro-condensed systems

Abstract

A device, system and method for detecting an inflammatory response modification. A plurality of sensor readings are obtained from an individual over a period of time. Over the period of time, at least a subset of the plurality of sensor readings are computed into a plurality of timestamped records. Applying an inflammatory response variability model on the plurality of timestamped records, an indicator of variation is identified for one or more values for at least one inflammatory biomarker for the individual. A deterioration in a medical condition of the individual may be predicted from the indicator when the inflammatory response variability model indicates a valid increase of the one or more values. An improvement may be predicted from the indicator when the inflammatory response variability model indicates a valid decrease of the one or more values.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/01 - Measuring temperature of body parts
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/024 - Measuring pulse rate or heart rate
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

There is provided a detection system for detecting an analyte in a sample. The detection system contains a microfluidic chip which has an inlet adapted to receive the sample, an incubation chamber, a sensing chamber, and an outlet. The detection system has a suction membrane in fluid communication with the outlet of the microfluidic chip, and an actuator for applying or relieving pressure from the suction membrane which modifies the air pressure in the microfluidic chip and drives a flow of the sample in the microfluidic chip. Finally, a detection apparatus is also provided for measuring a signal of the analyte in the sensing chamber.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present disclosure provides CRISPR/Cas9 ribonucicoprotein compositions comprising chemically modified CRISPR RNA (crRNA) guide and trans-acting CRISPR RNA (traerRNA) components. Methods of using the disclosed CRISPR/Cas9 ribonucleoprotein compositions are also provided.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A quantum magnetometer for measuring a magnetic field is provided. A Pauli Spin Blockade (PSB) system having, the at least discrete physical feature with a given spin state tunnel coupled to each of a source and a drain, is provided. The at least discrete physical feature is positioned between the source and the drain. A detector is configured to detect a magnetic field-dependent spin state at one or more of the source lead or the drain lead. An amplifier is configured to amplify the detected magnetic field-dependent transport current in some inventive embodiments.

IPC Classes  ?

• G01R 33/02 - Measuring direction or magnitude of magnetic fields or magnetic flux

Abstract

A ventilator adaptor for converting a ventilator having an inspiratory port and an expiratory port from single patient use to multiple patient use is disclosed. The ventilator adaptor includes an inspiratory splitter, and expiratory splitter and a controller. The inspiratory splitter is attachable to the inspiratory port of the ventilator, and at least two inspiratory branches which are each connectable to a different patient. The expiratory splitter is attachable to the expiratory port of the ventilator, and at least two expiratory branches which are each connectable to the respective different patient. The controller separately controls at least one inspiratory parameter of an inspired fluid in each of the at least two inspiratory branches and/or at least one expiratory parameter of an expired fluid in each of the at least two expiratory branches. A ventilator system having the ventilator adaptor, and methods for ventilating at least two patients are also disclosed.

IPC Classes  ?

• A61M 16/08 - BellowsConnecting tubes
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases

Abstract

A method for decoding data comprises receiving a sequence of symbols from a data sender over a noisy data channel. At a first decoder, a first search for a candidate error pattern is performed, within a search region, among a plurality of candidate error patterns, and an indication of a failure of the first search is output to a second decoder when no candidate error pattern is found within the search region. At the second decoder, a second search is performed, in parallel with the first search, for the candidate error pattern by evaluating the candidate error patterns for codebook membership based on the sequence of symbols, one or more of the candidate error patterns being skipped from the second search based on the indication of the failure of the first search. The sequence of symbols is decoded based on an outcome of the first search and the second search.

IPC Classes  ?

• H03M 13/39 - Sequence estimation, i.e using statistical methods for the reconstruction of the original codes

Abstract

The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 38/23 - Calcitonins
• A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

We provide cellulose-based filaments comprising a negatively charged cellulose derivative bearing anionic functional groups as well as bubble-free films and 3D objects comprising partially decarboxylated carboxymethyl cellulose, wherein these cellulose derivatives have a charge content of less than or equal to about 1.4 mEq/g of cellulose. The filaments have a diameter of between about 1 μm and about 50 μm. Method of producing these filaments and bubble-free films and 3D objects are also provides. These methods comprise extrusion or immersion into a coagulation bath. Films can be overlaid or bent to form 3D objects.

IPC Classes  ?

• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• C08B 11/12 - Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals

Abstract

A real-time, in situ and automated technology and method for dynamic observation of airborne viruses has been developed, and its application for airborne viruses, using a model virus, MS2 bacteriophage, and SARS-COV-1 RNA, has been demonstrated. There is described a method of performing measurements using a digital in-line holographic microscope (DIHM). The method generally has: propagating a light beam through a pinhole, across a medium including particles, and to a sensor; acquiring, with the sensor, a plurality of holograms, the holograms including scattering information of the particles; and determining, from a reconstruction of the holograms, at least one of shape, size, intensity and phase of the particles from the scattering information of said particles.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/22 - Processes or apparatus for obtaining an optical image from holograms

Abstract

A real-time, in situ and automated technology and method for dynamic observation of airborne viruses has been developed, and its application for airborne viruses, using a model virus, MS2 bacteriophage, and SARS-CoV-1 RNA, has been demonstrated. There is described a method of performing measurements using a digital in-line holographic microscope (DIHM). The method generally has: propagating a light beam through a pinhole, across a medium including particles, and to a sensor; acquiring, with the sensor, a plurality of holograms, the holograms including scattering information of the particles; and determining, from a reconstruction of the holograms, at least one of shape, size, intensity and phase of the particles from the scattering information of said particles.

IPC Classes  ?

• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/0227 - Investigating particle size or size distribution by optical means using imagingInvestigating particle size or size distribution by optical means using holography
• G03H 1/04 - Processes or apparatus for producing holograms

Abstract

In the absence of vaccines, chemotherapy is the main tool for treating parasitic diseases. As emergent resistant strains limit the utility of the few viable clinical options, new therapy is urgently needed to fight parasitic diseases. The present application relates to anisomycin analogs of Formula (I) or prodrug, solvates or pharmaceutically acceptable salts thereof, as well as to pharmaceutical compositions comprising same. These anisomycin analogs, prodrugs, solvates, or pharmaceutically acceptable salts thereof may be used for the treatment of parasitic infections and diseases, including protozoan diseases such as trypanosomiasis, leishmaniasis or toxoplasmosis.

IPC Classes  ?

• C07D 207/12 - Oxygen or sulfur atoms
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 33/00 - Antiparasitic agents
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

There is described a substrate for a semiconductor device. The substrate generally has a semiconductor wafer; an intermediate nanowire layer having a plurality of nanowires each having in succession a base portion mounted to the semiconductor wafer, an elongated body portion extending away from the semiconductor wafer, and a tip portion; and a buffer layer of aluminum nitride being made integral to the tip portions of the plurality of nanowires.

IPC Classes  ?

• H01L 33/12 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a stress relaxation structure, e.g. buffer layer
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
• H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
• H01L 33/40 - Materials therefor

Abstract

There is provided a detection system for detecting an analyte in a sample. The detection system contains a microfluidic chip which has an inlet adapted to receive the sample, an incubation chamber, a sensing chamber, and an outlet. The detection system has a suction membrane in fluid communication with the outlet of the microfluidic chip, and an actuator for applying or relieving pressure from the suction membrane which modifies the air pressure in the microfluidic chip and drives a flow of the sample in the microfluidic chip. Finally, a detection apparatus is also provided for measuring a signal of the analyte in the sensing chamber.

IPC Classes  ?

• G01N 1/00 - SamplingPreparing specimens for investigation
• G01N 1/28 - Preparing specimens for investigation
• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means

Abstract

There is provided a system and a method for determining a capacity for consciousness of a person. Neuroimaging data acquired by a neuroimaging system before, during, and following an exposure of the person to a neurophysiological perturbation agent having anesthetic properties is obtained. From the neuroimaging data, a degree of reconfiguration exhibited by a functional brain network of the person as a result of the exposure to the neurophysiological perturbation agent is determined. A measure of the capacity for consciousness of the person is computed based on the degree of reconfiguration exhibited by the functional brain network.

IPC Classes  ?

• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61B 5/372 - Analysis of electroencephalograms
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

There is provided a system and a method for determining a capacity for consciousness of a person. Neuroimaging data acquired by a neuroimaging system before, during, and following an exposure of the person to a neurophysiological perturbation agent having anesthetic properties is obtained. From the neuroimaging data, a degree of reconfiguration exhibited by a functional brain network of the person as a result of the exposure to the neurophysiological perturbation agent is determined. A measure of the capacity for consciousness of the person is computed based on the degree of reconfiguration exhibited by the functional brain network.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/369 - Electroencephalography [EEG]

Abstract

The disclosure relates to a compound of formula wherein Y, X, Ra, Rb, R1 and R2 are defined herein, PVC compositions comprising the compounds disclosed herein, as well as methods for modulating properties of a PVC, including reducing or preventing the formation of observable gas checks in calendered films, or other mechanical properties such as tensile strength and/or glass transition temperature. The disclosure relates to a compound of formula wherein Y, X, Ra, Rb, R1 and R2 are defined herein, PVC compositions comprising the compounds disclosed herein, as well as methods for modulating properties of a PVC, including reducing or preventing the formation of observable gas checks in calendered films, or other mechanical properties such as tensile strength and/or glass transition temperature.

IPC Classes  ?

• C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
• C08J 5/18 - Manufacture of films or sheets
• C08K 5/11 - EstersEther-esters of acyclic polycarboxylic acids

Abstract

The optical interrogation device can have a substrate; an insulating layer supported by the substrate; a plasmonic layer supported by the substrate via the insulating layer; a cavity extending across both the plasmonic layer and the insulating layer to a bottom adjacent the substrate, the cavity being sized to receive a particle; and a layer of 2D material covering the substrate and defining the bottom of the cavity. The process of optically interrogating the particle can include the layer of 2D material attracting the particle into the cavity across the upper end, and, while the particle is in the cavity, acquiring an optical signal including a spectral signature of the particle.

IPC Classes  ?

• G01N 15/10 - Investigating individual particles

Abstract

A method for overlaying an image on a physical object is described. The method includes: instantiating a common coordinate system that unifies a first coordinate system and a second coordinate system; dynamically recognizing the physical object in the common coordinate system using at least one sensor; aligning an image map with a model map of the dynamically recognized physical object in the common coordinate system; and displaying the image in a physical space overlaid on the physical object using a display of an extended reality (XR) device. A corresponding system and a computer-readable medium are also described.

IPC Classes  ?

• G06T 19/00 - Manipulating 3D models or images for computer graphics
• G02B 27/01 - Head-up displays

Abstract

Methods for mapping coordinates to a common coordinate system are taught. They include converting a model of an object to a model map, converting an image that is a is a representation of the object to an image map, generating a transform matrix encoding rotations, converting the transform matrix to a quaternion, recognizing common features in the image and in the model, extracting hologram coordinates and world coordinates of significant points from the common features, computing a transformation to map the model map to the hologram coordinate system, creating a common coordinate system, and computing transformations to map the image and the model to the common coordinate system. The methods can be used for tracking real-world objects and overlaying holograms onto them. They can be used in systems that include a sensor to capture a model from the object, a processor that performs one of the methods, and a light-emitting device that displays a hologram of the image overlaid onto the object.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• G06T 3/20 - Linear translation of whole images or parts thereof, e.g. panning
• G06T 19/00 - Manipulating 3D models or images for computer graphics

Abstract

The specification describes assemblies of rotary components in which a magnetic engagement is used as a negative incremental stiffness component and a torsion spring is used as a positive incremental stiffness component to provide new or improved meta-functionalities.

IPC Classes  ?

• H01F 7/18 - Circuit arrangements for obtaining desired operating characteristics, e.g. for slow operation, for sequential energisation of windings, for high-speed energisation of windings
• F16F 1/48 - Springs made of plastics, e.g. rubberSprings made of material having high internal friction characterised by the mode of stressing loaded mainly in torsion
• F16F 15/121 - Suppression of vibrations in rotating systems by making use of members moving with the system using elastic members or friction-damping members, e.g. between a rotating shaft and a gyratory mass mounted thereon using springs as elastic members, e.g. metallic springs

Abstract

The present disclosure relates to improvements in the field of water treatment, and more particularly to the separation step in a water treatment process. There is provided a method of separating contaminants from contaminated water. A fibrous treatment agent is provided into the contaminated water. The fibrous treatment agent has a length of about 100 pm and a diameter of at least 5 pm. The fibrous treatment agent is allowed to associate with the contaminants forming floes comprising a size of at least 1000 pm. The floes are physically separated from the contaminated water.

IPC Classes  ?

• C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
• C02F 1/00 - Treatment of water, waste water, or sewage
• C02F 1/24 - Treatment of water, waste water, or sewage by flotation
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

It is provided a cell macroencapsulation device for implanting cells in a recipient comprising cells encapsulated in a porous membrane, wherein the porous membrane consists of a sugar network coated with a polymeric solution comprising porogen, which can be used as a graft to transplant islets while protecting the graft from the immune system as well as providing enhanced convection and diffusion to ensure long-term cell survival and physiological insulin delivery.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 9/50 - Microcapsules
• A61K 35/39 - PancreasIslets of Langerhans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

System and method for displaying reaction animations that represent audience reactions to content. A reaction measurement module receives video data featuring at least one audience user from at least one video capture device. The reaction measurement module processes the video data to determine reaction data based on characteristics of the audience user's head. The reaction data is passed to a server and an animation-generation module generates animation data based on the reaction data. The animation data is passed to a user device for display. In some embodiments, the reaction animation(s) are displayed with the content in real or near real time. In other embodiments, the reaction animations are recorded for later viewing. In some embodiments, the animation(s) each represent multiple audience users.

IPC Classes  ?

• G06T 13/80 - 2D animation, e.g. using sprites
• G06T 7/70 - Determining position or orientation of objects or cameras
• G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions

Abstract

Provided herein compositions and methods including bioprinted tissue fibers comprising precisely patterned cancerous and non-cancerous cells that are capable of recapitulating a desired tumor microenvironment in vitro. The subject tissue models enable the automated high throughput screening of anti-cancer therapies in a biologically -relevant human system, and can be further personalized with patient-specific cells.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• B81C 3/00 - Assembling of devices or systems from individually processed components
• C12N 5/09 - Tumour cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/078 - Cells from blood or from the immune system
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G09B 23/30 - Anatomical models
• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells

Abstract

A formation method is provided. During this formation method, a metallic substrate is provided. A coating is deposited onto the metallic substrate using a suspension plasma spray process. The coating is formed from or otherwise includes copper oxide.

IPC Classes  ?

• C23C 4/06 - Metallic material
• C23C 4/11 - Oxides
• C23C 4/134 - Plasma spraying
• C23C 24/04 - Impact or kinetic deposition of particles

Abstract

There is provided a method of producing C1 oxygenated products with a GaN catalyst. The C1 oxygenated products are preferably methanol and formic acid. The method is optionally selective for methanol or formic acid. The GaN catalyst and an aqueous phase are provided in a reactor having a closed environment. 0.1 to 0.55 bar of methane and from 0 to 10 bar of oxygen are introduced in the reactor. The reactor is irradiated with ultra-violet light until C1 oxygenated products such as methanol and formic acid are obtained.

IPC Classes  ?

• C07C 27/16 - Processes involving the simultaneous production of more than one class of oxygen-containing compounds by oxidation of hydrocarbons with other oxidising agents
• B01J 23/08 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of gallium, indium or thallium
• C01B 21/06 - Binary compounds of nitrogen with metals, with silicon, or with boron

IPC Classes  ?

• A01N 25/10 - Macromolecular compounds
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• C08J 7/02 - Chemical treatment or coating of shaped articles made of macromolecular substances with solvents, e.g. swelling agents
• C08J 7/056 - Forming hydrophilic coatings
• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

Abstract

The present application relates to surface modification of polymers mesh, net or textile. More specifically, the present application relates to methods for modifying the surface of polymers and uses of the modified polymers for loading a bioactive compound. The present application includes use of the surface-modified polymers in agricultural applications, such as a pest control device or an exclusion net, for repelling, disrupting feeding, confusing or inhibiting the mating of, knocking down, sterilizing or killing a target pest species.

IPC Classes  ?

• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
• A01N 25/10 - Macromolecular compounds
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• A01N 61/00 - Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
• A01P 15/00 - Biocides for specific purposes not provided for in groups
• C08J 7/02 - Chemical treatment or coating of shaped articles made of macromolecular substances with solvents, e.g. swelling agents
• C08J 7/056 - Forming hydrophilic coatings

Abstract

There is provided a method for producing SC-BNNS and SC-BCNNS. A thermal plasma is provided at a plasma zone of a reaction chamber having an outlet opposite the plasma zone, a condensation zone and a growth zone downstream. The gas flows in the chamber have a laminar flow which provides a controlled residence time in a nucleation temperature field. A plasma-source gas flow is provided and has a plasma-source gas, and a sheath gas flow including nitrogen-containing gas to provide an excess of nitrogen. A boron source is provided to the thermal plasma through a probe to provide boron atomic species. A carbon source is provided for the production of SC-BCNNS. The process includes a controlled quenching step in the condensation zone followed by two-dimensional nucleation of SC-BNNS or SC-BCNNS in the growth zone, and the pressure in the chamber is maintained between 20 to 200 kPa.

IPC Classes  ?

• C01B 21/064 - Binary compounds of nitrogen with metals, with silicon, or with boron with boron
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

It is provided a process for producing lactosucrose from a source of lactose such as whey permeate and a source of sucrose as well as a source of both lactose/sucrose such as chocolate milk to enzymatically generating in situ lactosucrose, and fructosylate phenolic compounds contained therein, the process comprising contacting the dairy starting material (containing sucrose) with a levansucrase (LS), which can be immobilized on a solid support, selected from Bacillus amyloliquefaciens (ATCC 23350), Gluconobacter oxydans (strain 621H) (LS1), Vibrio natriegens NBRC 15636 (LS2), Novosphingobium aromaticivorans (LS3), and Burkholderia graminis C4D1M (LS4), or a combination thereof.

IPC Classes  ?

• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A23C 23/00 - Other dairy products

Abstract

There is described a solid reservoir reference electrode having a first layer of a metal; a second layer of a salt of the metal and a non-metallic species atop the first layer; a third layer of an electrolyte salt atop the second layer, the electrolyte salt including the non-metallic species; and a fourth layer of an inert polymer atop the third layer; wherein the electrolyte salt is soluble in an electrolytic solution receivable atop the fourth layer; the fourth layer, when contacted with the electrolyte solution, has first channels allowing the electrolytic solution to flow through the fourth layer; the third layer has second channels formed therein upon dissolution of the electrolyte salt by the electrolytic solution flowing through the first channels of the fourth layer; and the electrolytic solution is in fluid communication with the salt of the metal of the second layer through the first and second channels.

IPC Classes  ?

• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• A61B 5/263 - Bioelectric electrodes therefor characterised by the electrode materials
• C25B 11/00 - ElectrodesManufacture thereof not otherwise provided for
• C25D 17/10 - Electrodes

Abstract

The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule. In some aspects, the synthetic oligonucleotides include a 2′-deoxy-2′-fluoroarabinonucleotide (2′-FANA)-modified nucleotide sequence. In some embodiments, the 2′-FANA-modified nucleotide sequence inhibits dimerization of retroviral genomes (e.g., an HIV genome). Other embodiments include methods of inhibiting expression of a retrovirus using the synthetic oligonucleotide, and methods of treating or preventing a retroviral infection.

IPC Classes  ?

• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

There is provided an energy storage device, comprising a first electrode having a plurality of electrons stored thereon, a second electrode having a plurality of holes stored thereon, the second electrode spaced from the first electrode to define a volume therebetween, a supporting medium disposed in the volume between the first electrode and the second electrode, the supporting medium comprising at least one counterion species, and a plurality of nanoparticle elements provided in the volume, adjacent at least one of the first electrode and the second electrode, the plurality of nanoparticle elements configured to store the electrons therein at different energy levels using quantized capacitance.

IPC Classes  ?

• H01G 11/36 - Nanostructures, e.g. nanofibres, nanotubes or fullerenes
• H01G 11/56 - Solid electrolytes, e.g. gelsAdditives therein
• H01G 11/58 - Liquid electrolytes
• H01G 11/52 - Separators
• H01G 11/86 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof specially adapted for electrodes

Abstract

There is provided an energy storage device, comprising a first electrode having a plurality of electrons stored thereon, a second electrode having a plurality of holes stored thereon, the second electrode spaced from the first electrode to define a volume therebetween, a supporting medium disposed in the volume between the first electrode and the second electrode, the supporting medium comprising at least one counterion species, and a plurality of nanoparticle elements provided in the volume, adjacent at least one of the first electrode and the second electrode, the plurality of nanoparticle elements configured to store the electrons therein at different energy levels using quantized capacitance.

IPC Classes  ?

• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• H01G 4/005 - Electrodes
• H01G 4/018 - Dielectrics
• H02J 15/00 - Systems for storing electric energy

Abstract

There are described a method and system for obtaining data at a plurality of time intervals throughout a task performed by a user, the data generated by a control device manipulated by the user while performing the task; determining at least one task metric from the data, the at least one task metric associated with the task; using the at least one task matric to assign a value to at least one quality assessment metric at each time interval throughout the task based on a progression curve having a novice skill level at a first end of the curve, an expert skill level at a second end of the curve opposite to the first end, and undefined skill levels in between, the at least one quality assessment metric associated with the task; and displaying in real-time a first time-varying graphical indicator indicative of the value of the at least one quality assessment metric.

IPC Classes  ?

• G09B 19/00 - Teaching not covered by other main groups of this subclass
• G09B 9/00 - Simulators for teaching or training purposes
• G06T 19/00 - Manipulating 3D models or images for computer graphics

Abstract

A neuromelanin sensitive magnetic resonance imaging (“MRI”) technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to one or more neurological conditions.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

The present invention relates to a device for intraoperatively disinfecting a bone prosthesis (7) using bioelectric effect. Advantageously, the device comprises an array (1) that can be adapted to the shape of the bone prosthesis (7), wherein the array (1) is provided with an arrangement of electrodes (2) designed to connect to a programmable controller (11) for supplying current, designed to perform a bioelectric treatment on the prosthesis (7). The invention also relates to a disinfection system comprising the device connected to the programmable controller (11) for supplying current, and to a method for activating same.

IPC Classes  ?

• A61L 2/03 - Electric current, e.g. electrolysis

Abstract

There is provided a hemostatic bioadhesive including from 0.5 to 5 w/v % of chitosan or alginate measured as a weight percent of chitosan or alginate with respect to a total dry volume of the hemostatic bioadhesive, the chitosan or alginate being crosslinked and forming a first polymer network; from 0.5 to 13 w/v % of polyacrylamide or polyethylene glycol measured as a weight percent of polyacrylamide or polyethylene glycol with respect to the total dry volume of the hemostatic bioadhesive, the polyacrylamide or polyethylene glycol being crosslinked and forming a second polymer network, wherein the first polymer network and the second polymer network form a dissipative polymer matrix; and from 0 to 100 v/v % of an adhesive liquid infused in the dissipative polymer network. The hemostatic bioadhesives comprise interconnected pores in the dissipative polymer matrix having a size of 20 to 400 µm.

IPC Classes  ?

• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials

IPC Classes  ?

• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials

Abstract

A method for forming cell spheroids in a fluidic system, includes: injecting a mixture including cells embedded in a biomaterial matrix into a channel; generating vortices in the mixture flowing within the channel; trapping the cells using the vortices to form clusters of cells until the cells of the clusters of cells adhere to one another via the biomaterial matrix thereby forming the cell spheroids; and retrieving the cell spheroids from the channel.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

A system for mitigating temporomandibular joint disorders, comprising: a support to be worn by a wearer; an array of vibration units mounted to the support and each including an actuator and a vibrating pad in driving engagement with the actuator, the vibration units including a right mandible-engaging unit, a left mandible-engaging unit, and a sternum-engaging unit, the right mandible-engaging unit including a right mandible-engaging vibrating pad, the left mandible-engaging unit including a left mandible-engaging vibrating pad, and the sternum-engaging unit including a sternum-engaging vibrating pad; and a controller in communication with the actuators of each of the vibration units, the controller configured to activate one or more of the actuators in order to induce vibration of the vibrating pad of the respective vibration unit at a selected frequency and amplitude.

IPC Classes  ?

• A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibrationSuction-vibration massageMassage with moving diaphragms with electric or magnetic drive

Abstract

The oscillating device and system of the present disclosure is intended to be used as a physiotherapy appliance for clinical conditions having an abnormal muscular tone in the face and neck area and habitual (acquired) abnormal position of the lower jaw (mandible) and neck. The system for temporomandibular joints includes mandible-engaging pads for engaging a mandible of a user, a sternum-engaging pad for engaging a sternum of the user, and an oscillating system operatively connected to the mandible-engaging pads and the sternum-engaging pad, the oscillating system including at least one actuator operable to induce vibrations of the mandible-engaging pads and the sternum-engaging pad.

IPC Classes  ?

• A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
• A61F 5/56 - Devices for preventing snoring
• A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
• A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibrationSuction-vibration massageMassage with moving diaphragms with electric or magnetic drive

Abstract

There is provided an optical processing unit comprising a first Mach-Zehnder interferometer (MZI) and a second MZI optically coupled to the first MZI, each of the first MZI and the second MZI having a first internal waveguide arm and a second internal waveguide arm configured to propagate optical modes therein, a first phase shifter optically coupled to the first internal waveguide arm of the first MZI and configured to impart a same first phase shift to the optical modes, a second phase shifter optically coupled to the first internal waveguide arm of the second MZI and configured to impart a same second phase shift to the optical modes, and a third phase shifter optically coupled to the second internal waveguide arm of the second MZI and configured to impart a third phase shift to the different optical modes, the third phase shift having a different value for each of the optical modes.

IPC Classes  ?

• G06E 1/00 - Devices for processing exclusively digital data
• G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference
• G06E 1/04 - Devices for processing exclusively digital data operating upon the order or content of the data handled for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation

IPC Classes  ?

• G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference
• G06E 1/00 - Devices for processing exclusively digital data
• G06E 1/04 - Devices for processing exclusively digital data operating upon the order or content of the data handled for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation

Abstract

It is provided a process for producing lactosucrose from a source of lactose such as whey permeate and a source of sucrose as well as a source of both lactose/sucrose such as chocolate milk to enzymatically generating in situ lactosucrose, and fructosylate phenolic compounds contained therein, the process comprising contacting the dairy starting material (containing sucrose) with a levansucrase (LS), which can be immobilized on a solid support, selected from Bacillus amyloliquefaciens (ATCC 23350), Gluconobacter oxydans (strain 621H) (LS1), Vibrio natriegens NBRC 15636 (LS2), Novosphingobium aromaticivorans (LS3), and Burkholderia graminis C4D1M (L54), or a combination thereof.

IPC Classes  ?

• A23C 9/12 - Fermented milk preparationsTreatment using microorganisms or enzymes
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 38/45 - Transferases (2)
• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/10 - Transferases (2.)
• C12P 19/00 - Preparation of compounds containing saccharide radicals
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins

Abstract

The present disclosure provides an immunogenic composition comprising an emulsion of an epitope or a nucleic acid molecule. The emulsion comprises an oil phase and a water phase. The emulsion is an oil-in-water emulsion and/or a nanoemulsion. The epitope is present on a peptide or a polypeptide derived from Schistosoma sp. and can optionally be glycosylated. The immunogenic composition (which can be provided as a pharmaceutical composition or as a vaccine) can be used to prevent, treat or alleviation the symptoms of a Schistosoma sp. infection.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/02 - Inorganic compounds
• A61P 37/04 - Immunostimulants

Abstract

The present disclosure provides a combination therapy for treating breast cancer comprising an inhibitor of the mTOR pathway and an activator of the Hippo pathway. Also provided are methods of treating breast cancer using the combination therapy disclosed herein.

IPC Classes  ?

• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 35/00 - Antineoplastic agents

Abstract

GaN-based nanowire heterostructures have been intensively studied for applications in light emitting diodes (LEDs), lasers, solar cells and solar fuel devices. Surface charge properties play a dominant role on the device performance and have been addressed within the prior art by use of a relatively thick large bandgap AlGaN shell covering the surfaces of axial InGaN nanowire LED heterostructures has been explored and shown substantial promise in reducing surface recombination leading to improved carrier injection efficiency and output power. However, these lead to increased complexity in device design, growth and fabrication processes thereby reducing yield/performance and increasing costs for devices. Accordingly, there are taught self-organising InGaN/AlGaN core-shell quaternary nanowire heterostructures wherein the In-rich core and Al-rich shell spontaneously form during the growth process.

IPC Classes  ?

• H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
• H01L 33/08 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a plurality of light emitting regions, e.g. laterally discontinuous light emitting layer or photoluminescent region integrated within the semiconductor body
• H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
• H01S 5/10 - Construction or shape of the optical resonator
• H01S 5/323 - Structure or shape of the active regionMaterials used for the active region comprising PN junctions, e.g. hetero- or double- hetero-structures in AIIIBV compounds, e.g. AlGaAs-laser
• H01L 33/18 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region

Abstract

A cathode active material including a compound represented by Formula 1 and having an olivine structure: A cathode active material including a compound represented by Formula 1 and having an olivine structure: A cathode active material including a compound represented by Formula 1 and having an olivine structure: wherein in Formula 1, 0≤α<1, 0.01≤x≤0.1, and 0.01≤y≤0.1, and M in Formula 1 is a divalent element, a trivalent element other than In, a tetravalent element, a pentavalent element, or a combination thereof.

IPC Classes  ?

• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy

Abstract

System and method for generating candidate vocabulary words and presenting them to a user. The system compares an input image to reference images, based on text descriptions of the images, and determines relevant images. Stories associated with the relevant images are then analyzed to determine frequent words in the stories. In one embodiment, the frequent words are presented to the user as candidate words. In another embodiment, a vocabulary database is first accessed to determine other words that are associated with the frequent words in the stories. The frequent words in the stories and the other words from the vocabulary database are then provided to the user as candidate vocabulary words. The user can select desired candidate words through their computing device. In some embodiments, the stories are clustered together before word frequency is analyzed.

IPC Classes  ?

• G06F 16/538 - Presentation of query results
• G06F 40/242 - Dictionaries
• G06F 40/30 - Semantic analysis
• G06F 16/55 - ClusteringClassification

Abstract

There is provided a method of treating obesity and/or hypertension in a subject in need thereof by administering a therapeutically effective amount of a low molecular weight levan or a pharmaceutical composition comprising the low molecular weight levan and a pharmaceutically acceptable excipient.

IPC Classes  ?

• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 9/12 - Antihypertensives

Abstract

There is provided a method of treating obesity and/or hypertension in a subject in need thereof by administering a therapeutically effective amount of a low molecular weight levan or a pharmaceutical composition comprising the low molecular weight levan and a pharmaceutically acceptable excipient.

IPC Classes  ?

• A61K 31/733 - Fructosans, e.g. inulin
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 9/12 - Antihypertensives
• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C08B 37/18 - Reserve carbohydrates, e.g. glycogen, inulin, laminarinDerivatives thereof
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins

Abstract

Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase. Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.

IPC Classes  ?

• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61P 35/00 - Antineoplastic agents
• A61K 33/243 - PlatinumCompounds thereof
• A61K 31/075 - Ethers or acetals
• A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/18 - Sulfonamides
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
• C07C 233/66 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
• C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
• C07C 275/40 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 257/04 - Five-membered rings
• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07H 15/207 - Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins

Abstract

There is provided a surface functionalized with cross linking groups adapted to receive antibodies and/or fragments thereof. The surface has an antibody binding biomolecule having a linker region which is covalently crosslinked to functional groups and an antibody binding region. The surface also has a cell interacting biomolecule having a linker region which is covalently crosslinked to functional groups of the surface and a cell interacting region that imparts functional attributes including cell adhesion, spreading, proliferation, differentiation and/or a functional response. The two biomolecules are present in independently controlled concentrations and have similar small molecular weights.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 11/06 - Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent

Abstract

A shell-based material, also referred to as a shellular or a shell-based mechanical metamaterial, is comprised of a plurality of unit cells that are each made of a curved shell, and contain at least one perforation on their snapping motif. The shell-based material has a predetermined number of structural stable states based on the snapping motif and on the at least one perforation. The predetermined number of structural stable states including a first structural stable state, for example an unloaded initial state, and a second structural stable state being different from the first structural stable state.

IPC Classes  ?

• F16F 1/377 - Springs made of plastics, e.g. rubberSprings made of material having high internal friction characterised by having a particular shape having holes or openings

Abstract

Theranostic compounds are provided having formula: (Ia), (Ib), or (Ic), or a salt thereof.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 35/00 - Antineoplastic agents
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/16 - Peri-condensed systems
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C09B 15/00 - Acridine dyes
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

There is described a biosensor apparatus. The biosensor apparatus generally has: a photodiode array having a first photon receiving face, a transparent substrate covering the first photon receiving face of the photodiode array, the transparent substrate having a second photon receiving face opposite the photodiode array, an electrically conductive coating covering the second photon receiving face of the transparent substrate, the electrically conductive coating being transparent and having two electrical contacts spaced apart from one another, and an analyte receiving area extending between the two electrical contacts of the electrically conductive coating.

IPC Classes  ?

• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 21/76 - ChemiluminescenceBioluminescence

Abstract

Disclosed herein are methods of treating neuropsychiatric and cognitive diseases, disorders, or conditions, such as social disfunction, with repeated doses of a modulator of the AMPA receptor and/or the 5-HT2A receptor.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 25/22 - Anxiolytics

Abstract

There is provided a system for circulating air. The system for circulating air has a concrete element that has an open cell porous matrix concrete. The concrete element has an inner surface opposite an outer surface. The inner surface faces an enclosed dwelling space of a building. The system for circulating air has an air circulation conduit in fluid flow communication with the outer surface of the concrete element, and a fan configured to circulate air along the air circulation conduit and through the open cell porous matrix, across a thickness of the concrete element, into the enclosed dwelling space.

IPC Classes  ?

• B01D 53/85 - Biological processes with gas-solid contact
• F24F 8/175 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by separation, e.g. by filtering using biological materials, plants or microorganisms
• B01D 53/44 - Organic components
• B01D 53/34 - Chemical or biological purification of waste gases

Abstract

There is provided a system for circulating air. The system for circulating air has a concrete element that has an open cell porous matrix concrete. The concrete element has an inner surface opposite an outer surface. The inner surface faces an enclosed dwelling space of a building. The system for circulating air has an air circulation conduit in fluid flow communication with the outer surface of the concrete element, and a fan configured to circulate air along the air circulation conduit and through the open cell porous matrix, across a thickness of the concrete element, into the enclosed dwelling space.

IPC Classes  ?

• A01G 9/24 - Devices for heating, ventilating, regulating temperature, or watering, in greenhouses, forcing-frames, or the like
• F24F 6/04 - Air-humidification by evaporation of water in the air using stationary unheated wet elements
• F24F 7/10 - Ventilation with ducting systems with forced air circulation, e.g. by fan with air supply, or exhaust, through perforated wall, floor or ceiling
• F24F 8/10 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying by separation, e.g. by filtering
• F24F 13/30 - Arrangement or mounting of heat-exchangers

Abstract

An energy conversion system includes a reactor vessel, a jacket disposed within the reactor vessel, the jacket having a wall that defines a chamber, a first end, and a second end opposite the first end, and a nozzle coupled to the reactor and arranged to direct a continuous flow of fuel at a flow rate into the chamber. The fuel including a mixture of a metal compound and water at a pressure that is greater than 221 bar. A cooling space is formed between the jacket and the reactor vessel and is operable to maintain a temperature of the fuel within the chamber between 374 and 800 degrees Celsius. A first gas outlet is in fluid communication with the chamber and is arranged to discharge a gas, and an outlet is in fluid communication with the chamber and is arranged to continuously discharge a reaction product and water.

IPC Classes  ?

• B01J 3/00 - Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matterApparatus therefor
• B01J 3/04 - Pressure vessels, e.g. autoclaves
• B01J 4/00 - Feed devicesFeed or outlet control devices
• B01J 7/02 - Apparatus for generating gases by wet methods
• B01J 16/00 - Chemical processes in general for reacting liquids with non-particulate solids, e.g. sheet materialApparatus specially adapted therefor
• B01J 19/24 - Stationary reactors without moving elements inside
• C01B 3/08 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents with metals

Abstract

It is provided the synthesis of an aptamer-like encoded oligomer (ALEnOmer), method of producing same and method of preparing a library of ALEnOmes. More particularly, the method of preparing ALEnOmer comprises coupling at least one phosphoramidite monomer with an orthogonal protecting group, and the ALEnOmer produces comprises a DNA coding strand covalently attached to an oligomer through a branching unit, wherein the oligomer has a degree of polymerization at least 5 and is an aptamer.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C07H 19/06 - Pyrimidine radicals

Abstract

There is provided herein, processes for synthesizing oligonucleotides using mechanochemical force to induce the formation of internucleotide linkages.

IPC Classes  ?

• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C07H 1/00 - Processes for the preparation of sugar derivatives

Abstract

A method for determining a anatomical cavity pressure comprising; obtaining a pressure value comprising a pressure applied to skin of the anatomical cavity by a vessel, the vessel having a first open end and a second end, the first end arranged to contact the skin to encase a portion of the skin, and the vessel being arranged such that a pressure can be applied through the vessel to the encased portion of the skin; obtaining a skin displacement value associated with the obtained pressure value, the skin displacement value comprising a distance of the encased portion of the skin from a baseline while the pressure is being applied; determining, by the processor, a pressure of the anatomical cavity using the obtained pressure value and the obtained skin displacement value, and based on a static force balance of the vessel and the encased portion of the skin while the pressure is being applied.

IPC Classes  ?

• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to polypeptides capable of limiting the replication of coronavirus and/ or nucleic acid molecules encoding polypeptides capable of limiting the replication of coronavirus, including those comprising a Nsp1-10 fusion and/or Nsp12. The present invention also relates to methods of using said polypeptides and/or nucleic acid molecules encoding said polypeptides for the treatment coronavirus infections in a subject in need thereof.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 31/14 - Antivirals for RNA viruses
• C07K 19/00 - Hybrid peptides
• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/86 - Viral vectors

Abstract

It is described a composite hydrogel containing egg white and alginate (EWA) polymers, and a method of producing same, wherein the alginate is cross-linked using frozen calcium chloride disks, creating a scaffold for cells comprising a slow-rate ions diffusion through the matrix, ensuring a homogenous crosslink and smooth surface.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues